Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Citius Pharmaceuticals (NASDAQ:CTXR) in a report released on Tuesday,Benzinga reports. HC Wainwright currently has a $4.00 price objective on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.18) EPS and FY2026 earnings at $0.05 EPS.

Separately, EF Hutton Acquisition Co. I upgraded Citius Pharmaceuticals to a “strong-buy” rating in a research note on Monday, July 15th.

Citius Pharmaceuticals Trading Down 14.9 %

CTXR stock opened at $0.33 on Tuesday. The firm has a 50-day moving average price of $0.44 and a 200-day moving average price of $0.60. Citius Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $1.07. The stock has a market capitalization of $59.35 million, a P/E ratio of -1.61 and a beta of 1.66.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). As a group, equities analysts predict that Citius Pharmaceuticals will post -0.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Armistice Capital LLC acquired a new stake in Citius Pharmaceuticals during the 2nd quarter worth approximately $5,928,000. Vanguard Group Inc. lifted its holdings in shares of Citius Pharmaceuticals by 1.5% during the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after purchasing an additional 104,889 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Citius Pharmaceuticals in the second quarter worth $118,000. Wealth Advisory Solutions LLC grew its stake in shares of Citius Pharmaceuticals by 33.1% in the third quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock worth $101,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Arkadios Wealth Advisors increased its holdings in Citius Pharmaceuticals by 33.3% in the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after purchasing an additional 50,000 shares during the period. Institutional investors and hedge funds own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.